Resource Center: FAQ

Patient information sheet explaining the phases of Suboxone® treatment including intake, induction, stabilization, maintenance, and medically supervised withdrawal.

These FAQs address topics such as the prevalence of opioid dependence, how treatment of opioid dependence with Suboxone® works, the side effects of the medication, and other common patient questions.

This document from the makers of Suboxone® addresses what opioid dependence is and how it can be treated.

Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) is approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.

This website from the makers of Suboxone® provides many helpful support tools and resources for patients taking buprenorphine for opioid dependence. It includes psychosocial tools (motivational quizzes, goal-setting tools) and medical information. This website is one component of Reckitt Benckiser's Here to Help campaign; it also includes care coordinators and care coaches who will help patients in the early stages of treatment to find and stay in treatment.

This patient handout - written in Spanish - answers basic questions such as "What is an opioid?," "What is opioid dependence?," "How common is opioid dependence?," "What is Suboxone?,"Can I switch from Methadone to Suboxone?," and "How long should I take Suboxone?," and more.

These FAQs - written in Spanish - address topics such as the prevalence of opioid dependence, how treatment of opioid dependence with Suboxone® works, the side effects of the medication, and other common patient questions.

Answers to basic Medicaid and Medicare coverage questions from SAMSHA's FAQs on buprenorphine.